JANET TU to Protein Kinase Inhibitors
This is a "connection" page, showing publications JANET TU has written about Protein Kinase Inhibitors.
Connection Strength
0.020
-
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 Mar; 19(3):500-506.
Score: 0.020
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.